Main Article Content
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Приказ МЗ Украины № 574 от 05.08.2009.
Heller S., Colagiuri S., Vaaler S., Wolffenbuttel B.H.R. et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes // Diabetic Medicine. — 2004. — Vol. 21. — P. 769-775.
De Leeuw I., Selam J.-L., Skeie S. et al. Insulin detemir-based used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin // Diabetes Obes. Metab. — 2005. — Vol. 7, № 1. — P. 73-82.
Garber A.J., Clauson P., Pedersen C.B., Kølendorf K. Lower risk of hypoglycemia with insulin detemir than with NPH insulin in older persons with type 2 diabetes: a pooled analysis of phase 3 trials // J. Am. Geriatric. Soc. — 2007. — 55(11). — 1735-40.
Meneghini L.F., Rosenberg K.H., Koenen C., Merilainen M.J., Luddeke H.J. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVETM // Diabetes Obes. Metab. — 2007. — 9(3). — 418-27.
Luddeke et al. PREDICTIVE™ — a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort // Diabetes, Obesity and Metabolism. — 2007. — 9. — 428-434.
Dornhorst A., Hernandez F.O., Koenen C., Lüddeke H.-J. Levemir (insulin Detemir) Reduces Weight and Improves Blood Glucose Levels Poster presentation at: 19th world congress of the International Diabetes Federation. — Capetown, South Africa, December 3–7, 2006.
Selam J.L., Koenen C., Weng W., Meneghini L. Improving glycemic control with insulin detemir using the 303 algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study // Curr. Med. Res. Opin. — 2008. — 24(1). — 11-20.
Porte D.Jr., Baskin D.G., Schwartz V.W. Insulin signaling in the central nervous system a critical role in metabolic homeostasis and disease from C. elegans to human // Diabetes. — 2005. — 54(5). — 1264-76.
Hennige A.M., Sartorius T. et al. Tissue selectivity of insulin detemir action in vivo // Diabetologia. — 2006. — 49. — 1274-1282.
Schwartz M.W. Brain parthways controlling food intake and body weight // Science. — 2000. — 289. — 2066-7.
Horden S.V.M., Wrigt J.E. et al. Comparison of effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-hr euglycaemic clamp // Diabetologia. — 2005. — 48. — 420-426.
Hermanse K., Tamer S. The advantage of less weight gain with baseline obesity when insulin Detemir rather than NPH insulin added to oral agents in Type 2 Diabetes // Diabetes. — 2005. — 54 (Suppl.1). — A 64.
Haak T. et al. Lower within subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes // Diabetes Obesity Metabolism. — 2005. — 7(1). — 56-64.
Постанова Кабінету міністрів України від 19 серпня 2009 р. № 877 «Про затвердження Державної цільової програми «Цукровий діабет»» на 2009–2013 роки.
Global guideline for Type 2 diabetes. — Brussels: International Diabetes Federation, 2005.
Nathan D.M. et al. Medical management of hyperglycaemia in type 2 Diabetes Mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes // Diabetologia. — 2009. — 52. — 17-30.
Va/DoD Clinical practice Guideline for the management of diabetes mellitus, August 2010, Version 4.0.
Road Maps To Achieve Glycemic Control in Type 2 Diabetes Mellitus // Endocrine Practice. — 2007. — Vol. 13, № 3 May/June.
Asakura T., Seino H. Dosing accuracy of two insulin pre-filled pens // Current Med. Research and Opinion. — 2008. — 24. — 1429-1434.
Valensi et al. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix® 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study // Int. J. Clin. Pract. — 2009. — 63, 3. — 522-531.